DERM Stock Forecast & Price Target

Journey Medical is well-positioned for success, with its strong portfolio of FDA-approved prescription drugs for the treatment of dermatological conditions and its focus on the dermatological segment. The company's recent national formulary add and negotiations with other large national formularies act as positive catalysts for future revenue growth. Additionally, Journey's Emrosi product is showing strong potential with a growing prescriber base and high refill rates, and management expects improved GTNs to further drive revenue growth in 2026. While there may be some short-term overhang due to revenue conversion, overall valuation is strong and the risks to achieving the $12 to $15 price target include competition, slower uptake of Emrosi, and regulatory and clinical risks in ongoing portfolio programs.

Journey Medical is a commercial-stage pharmaceutical company, with a current negative outlook from a financial analyst. Despite the company's focus on selling FDA-approved prescription drugs for dermatological conditions and its strong portfolio of products, there are concerns about its ability to generate significant revenue. The company's Q2 financial results showed a third consecutive quarter of positive non-GAAP profitability, but revenue growth of 23% was in line with expectations and its COGS of $6.1M yielded only a gross margin of 67%. In addition, there are risks from patent litigation and regulatory issues, as well as ongoing negotiations for international outlicensing of its products. Although management expects Emrosi to continue driving growth, there are concerns about the impact of elevated gross-to-net discounts on reported revenue. Based on these factors, the analyst has a negative outlook on Journey Medical's stock.